October 22, 2013
1 min read

InnoCore, Allergan sign license, collaboration agreement

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

InnoCore Pharmaceuticals has signed an exclusive license and collaboration agreement with Allergan, according to a news release.

Under the agreement, the companies will expand their existing collaboration and continue to develop long-acting ocular drug delivery products to treat ophthalmic diseases, the release said.

InnoCore will use its SynBiosys polymeric drug delivery platform to formulate Allergan’s proprietary drugs into pharmaceutical products that can provide sustained release for several months after a single ocular injection, according to the release.